Form 4 Filing for Philip Ron M

Philip Ron M, a director at Avalo Therapeutics, Inc., was granted 69 stock options on June 30, 2026, with an exercise price of $18.48 per share. These options are immediately 100% vested and have an expiration date of June 30, 2036. The options were acquired under transaction code "A". Following this transaction, Philip Ron M owns 69 shares of the underlying Common Stock. The filing was signed by Christopher Sullivan, Attorney-in-Fact, on July 2, 2026.